Immunotherapy of melanoma (Q34383950)

1 August 2017

1 reference

title

Immunotherapy of melanoma. (English)

1 reference

1 August 2017

1 reference

Smith C

1

1 reference

1 August 2017

Cerundolo V

series ordinal

2

1 reference

1 August 2017

publication date

1 September 2001

1 reference

1 August 2017

1 reference

1 August 2017

volume

104

1 reference

1 August 2017

issue

1

1 reference

1 August 2017

page(s)

1-7

1 reference

Structure of the gene of tum- transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

A listing of human tumor antigens recognized by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

Serological analysis of human tumor antigens: molecular definition and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

Structure, chromosomal localization, and expression of 12 genes of the MAGE family

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

Phenotypic analysis of antigen-specific T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

Differentiation of T regulatory cells by immature dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2001.01297.X

Characterization of the GAGE genes that are expressed in various human cancers and in normal testis

21 January 2018

1 reference

12 December 2020

Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events

1 reference

12 December 2020

Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.

1 reference

12 December 2020

Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides

1 reference

12 December 2020

MAGE-B5, MAGE-B6, MAGE-C2, and MAGE-C3: four new members of the MAGE family with tumor-specific expression

1 reference

12 December 2020

Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide

1 reference

12 December 2020

A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use

1 reference

12 December 2020

Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study

1 reference

12 December 2020

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

1 reference

12 December 2020

Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer

1 reference

12 December 2020

Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2

1 reference

12 December 2020

Donor T cells to treat EBV-associated lymphoma

1 reference

12 December 2020

Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases.

1 reference

12 December 2020

Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo

1 reference

12 December 2020

DNA-based immunization by in vivo transfection of dendritic cells

1 reference

12 December 2020

Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides

1 reference

12 December 2020

Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A

1 reference

12 December 2020

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

12 December 2020

Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.

1 reference

12 December 2020

Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay

1 reference

12 December 2020

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

1 reference

12 December 2020

Cutting edge: rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma

1 reference

12 December 2020

Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine

1 reference

12 December 2020

10.1046/J.1365-2567.2001.01297.X

Identifiers

DOI

1 reference

1 August 2017

1 reference